Physician profile
Christopher Charles Sutton
NPI 1558771220
$9,826.12
in general payments reported to CMS, 2019-2025
18 companies · $1,432 in 2025
The $1,432 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $209 · 2020: $28.27 · 2021: $576 · 2022: $15.31 · 2023: $187 · 2024: $7,379 · 2025: $1,432.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $4,090 · Food and Beverage: $2,598 · Travel and Lodging: $2,301 · Gift: $8.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $4,090.08 |
| Food and Beverage | $2,598.26 |
| Travel and Lodging | $2,300.89 |
| Gift | $8.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $6,787.04 | 2024-2025 | |
| Glaxosmithkline, LLC. | $802.64 | 2020-2025 | Nucala, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $743.08 | 2020-2025 | Breztri, Airsupra, Tezspire |
| Regeneron Healthcare Solutions, INC. | $286.09 | 2024-2025 | Dupixent |
| Grifols USA, LLC | $173.14 | 2021-2025 | Prolastin-C Liquid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $148.85 | 2024-2025 | Ofev |
| Genentech USA, INC. | $130.12 | 2019 | |
| Philips North America LLC | $125.39 | 2024-2025 | Vest Therapy Und, Encore, (8874) Incourage |
| Insmed, INC. | $115.68 | 2025 | Brinsupri, Arikayce |
| Verona Pharma, INC. | $102.68 | 2025 | Ohtuvayre |
| Ethicon INC. | $83.15 | 2021 | |
| Shire North American Group INC | $78.70 | 2019 | |
| Baxter Healthcare | $71.82 | 2022-2025 | Hillrom - Vest System Model 105 Home Care |
| Medtronic, INC. | $42.25 | 2023 | Illumisite |
| Genzyme Corporation | $41.41 | 2025 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $40.59 | 2024-2025 | Stelara, Tremfya |
| Electromed, INC. | $29.05 | 2024-2025 | Smartvest |
| Takeda Pharmaceuticals U.S.A., INC. | $24.44 | 2024 | Glassia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Sutton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.